NCT06510309 - Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 1, 2030

Conditions

LymphomaMarginal Zone LymphomaMZL

Interventions

DRUG

Venetoclax

B-cell lymphoma inhibitor, tablets taken orally per protocol.

DRUG

Rituximab

Anti-CD20 monoclonal antibody, 10mL or 50 mL single-use vials, via intravenous (into the vein) infusion per protocol.

Trial Locations (1)

Beth Israel Deaconess Medical Center, Boston